An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer
We established a novel ARRDEGs-based prognostic signature that predicts PCa progression and response to chemotherapy and targeted therapy. The integration of this signature with immune profiling and drug sensitivity analysis provides a valuable tool for precision oncology in PCa. Our findings highlight the potential of PLK1 inhibition as a therapeutic strategy to enhance enzalutamide efficacy and overcome resistance.
Authors
- Shirong Peng (ORCID: https://orcid.org/0000-0001-8905-3317)
- Tong Su (ORCID: https://orcid.org/0000-0002-4177-522X)
- Hai Huang (ORCID: https://orcid.org/0000-0002-6928-3198)
- Yuan Ou (ORCID: https://orcid.org/0000-0003-3781-0093)
- Ruihui Xie (ORCID: https://orcid.org/0000-0002-5254-6799)
- Qianghua Zhou (ORCID: https://orcid.org/0000-0001-7483-0478)
- Weilong Lin (ORCID: https://orcid.org/0000-0003-2713-5987)
- Bingliang Chen (ORCID: https://orcid.org/0009-0008-0757-7722)
- Zean Li
- Yu Duan (ORCID: https://orcid.org/0009-0006-3133-403X)
- Kaiwen Li (ORCID: https://orcid.org/0000-0002-6460-5768)
- Ruilin Zhuang
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1186/s12967-025-06457-8
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 10.63
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Natural Science Foundation of Guangdong Province
- Fundamental Research Funds for the Central Universities